Understanding how tumor and immune cell interactions affect cancer treatment resistance
Official title: Core 1: Tumor and Microenvironment Heterogeneity Core (TMH Core)
Funded at Salk Institute for Biological Studies · NIH-10883575 · Data updated 2026-11-12
This study is looking at how cancer cells and immune cells work together in tumors, which can make it harder for treatments to be effective, and it aims to find new ways to create better, personalized therapies for patients battling cancer.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project start | July 6, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $399,061 |
| NIH project number | 5P01CA265762-02 |
| Project ID | NIH-10883575 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma (PDA) who are undergoing treatment.
✕Less likely to help
Patients with cancers other than pancreatic ductal adenocarcinoma may not receive direct benefits from this research.
What this research studies
This research investigates the complex interactions between tumor cells and immune cells in the tumor microenvironment, focusing on how these interactions contribute to resistance against cancer therapies. By analyzing the diversity and localization of various immune and stromal cells, the research aims to uncover the mechanisms that allow tumors to evade treatment. Utilizing advanced techniques such as single-cell transcriptomics and digital spatial profiling, the project seeks to provide insights that could lead to more effective cancer therapies tailored to individual patients.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective cancer treatments that overcome resistance and improve patient outcomes.
How similar studies have gone: Previous research has shown success in understanding tumor microenvironments and their role in treatment resistance, indicating that this approach has potential for meaningful advancements.
Where this research is happening
-
Salk Institute for Biological Studies
La Jolla, United States Active
Researchers
- Principal investigator: Kaech, Susan M — Salk Institute for Biological Studies
- Study coordinator: Kaech, Susan M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.